TRT Clinic or Primary Care for Testosterone? (TRT Q&As)
Timeline
A 27-year-old man with prior anabolic steroid use asks about conflicting TRT approaches involving testosterone, clomiphene, anastrozole, compounded hormones, and letrozole. Dr. O’Connor emphasizes individualized, evidence-based care, questions routine aromatase inhibitor use, and stresses monitoring overall health rather than simply prescribing a standardized hormone protocol.
Dr. O’Connor reviews the member’s CBC and iron studies in the context of recently starting testosterone. He explains the importance of evaluating hemoglobin, hematocrit, iron, ferritin, and iron saturation together rather than interpreting an isolated result.
The member asks whether anything needs to be done about his low HDL. The discussion focuses more heavily on LDL and overall cardiovascular risk, while Dr. O’Connor also notes that metabolic health, diabetes, excess androgen exposure, and aromatase inhibitors can influence HDL.
Dr. O’Connor says there are no adequate clinical studies proving that long-term combined anabolic steroid use is safe even when health markers appear controlled. He discusses harm reduction and monitoring but emphasizes that risk varies by the individual and that keeping the ABCDs™ normal does not make supraphysiologic steroid use risk-free.
Dr. O’Connor frames continued steroid use as an individual risk-benefit decision and asks the member to consider his goals and personal appetite for risk. He emphasizes using the lowest exposure possible, understanding that complications can still occur, and repeatedly reassessing whether the desired physique or performance benefits justify the potential consequences.
Dr. O’Connor explains that iron markers need to be interpreted together because the body may be actively using stored iron for red blood cell production. In men using testosterone or other androgens, he emphasizes looking at ferritin alongside iron, saturation, hemoglobin, hematocrit, and the broader clinical picture rather than treating one laboratory value in isolation.
Video Summary
This Ask The Doc live Q&A focuses on how clinicians evaluate testosterone therapy using symptoms, laboratory trends, and overall health context together. The discussion explains why lab values alone rarely capture treatment success or failure. Energy levels, mood stability, sexual function, and physical performance are treated as interconnected clinical signals. The session highlights how individualized assessment replaces rigid protocol targets. Viewers gain clarity on how clinician judgment is applied when patient responses vary. Emphasis is placed on reassessment rather than immediate correction. Education remains central to effective decision-making.
Monitoring and safety considerations are woven throughout the conversation. Estradiol balance, hematocrit trends, and cardiometabolic risk awareness are discussed as ongoing responsibilities rather than one-time checkpoints. The session explains why gradual changes are often safer than abrupt interventions. Baseline risk factors such as body composition, insulin resistance, and cardiovascular history are incorporated into evaluation. Clinicians stress proportional responses to lab movement. Patterns over time are prioritized over isolated results. This reflects modern standards of hormone management.
Sexual health concerns appear repeatedly, linking hormone balance with vascular and prostate health. Erectile dysfunction is discussed as a multifactorial issue involving hormones, circulation, and overall health. Medication options are addressed within broader treatment planning rather than as standalone fixes. Prostate screening and urinary symptoms are framed through informed risk assessment. Fear-based messaging is avoided in favor of clarity. Communication between patient and clinician is emphasized. Personalization remains the guiding principle.
Drug Callouts
Condition Callouts
Key Takeaways
- Hormone therapy decisions rely on symptom patterns and longitudinal lab trends rather than single values.
- Estradiol balance can influence side effects and treatment tolerance.
- Hematocrit monitoring supports safer long-term testosterone therapy.
- Sexual health concerns often reflect overlapping hormonal and vascular factors.
- Personalized follow-up improves understanding and clinical outcomes.